Developing a treatment to prevent hearing loss from Cisplatin chemotherapy.
Development of UPR-Targeted Treatment for Cisplatin-Induced Ototoxicity.
['FUNDING_SBIR_1'] · JACARANDA BIOSCIENCES, INC. · NIH-11004730
This study is looking at new ways to protect your hearing from damage caused by a common chemotherapy drug called Cisplatin, which might be especially helpful for patients who are worried about losing their hearing during treatment.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JACARANDA BIOSCIENCES, INC. (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11004730 on ClinicalTrials.gov |
What this research studies
This research focuses on creating new compounds that can protect against hearing loss caused by Cisplatin, a common chemotherapy drug. The approach involves targeting the unfolded protein response (UPR) in the cochlea, which is crucial for preventing cell death and preserving hearing. By testing and optimizing these compounds in animal models, the researchers aim to establish a foundation for future human trials. Patients who experience hearing loss due to Cisplatin treatment may find this research particularly relevant.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who are receiving Cisplatin treatment and are at risk of developing hearing loss.
Not a fit: Patients who are not undergoing Cisplatin treatment or do not have a risk of hearing loss may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the incidence of hearing loss in patients undergoing Cisplatin chemotherapy.
How similar studies have performed: Previous research has shown promise in using UPR modulation to prevent hearing loss in animal models, indicating a potential for success in this novel approach.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- JACARANDA BIOSCIENCES, INC. — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHOUCHANE, MALEK — JACARANDA BIOSCIENCES, INC.
- Study coordinator: CHOUCHANE, MALEK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.